SCHEMBL6329787

SCHEMBL6329787

CCCC(CCC)C(=O)NC(C)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.54
HDAC2 Q92769 2/20 0.54
CHRM1 P11229 1/20 0.54
AKR1A1 P14550 1/20 0.54
CHRM3 P20309 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
ADRA1A P35348 1/20 0.54
HRH1 P35367 1/20 0.54
DRD3 P35462 1/20 0.54
SLC6A3 Q01959 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
MME P08473 3/20 0.52
ACE P12821 2/20 0.52
CPA1 P15085 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14434500 1.00 HDAC1 (0.54) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL5513528 0.85 MME (0.41) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL5380838 0.85 MME (0.41) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL5902137 0.83 MME (0.60) MMEACECPA1ACE2LTA4H
SCHEMBL6977604 0.82 HDAC8 (0.52) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL353712 0.81 CA2 (0.60) MMEACECPA1ACE2LTA4H
SCHEMBL5936918 0.81 CA2 (0.60) MMEACECPA1ACE2LTA4H
SCHEMBL5279569 0.81 CA2 (0.60) MMEACECPA1ACE2LTA4H
SCHEMBL23029892 0.80 DPP9 (0.51) HDAC1HDAC2CHRM1AKR1A1CHRM3
SCHEMBL6329799 0.80 ACE (0.49) HDAC1HDAC2CHRM1AKR1A1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943163-B2 7-Alkyl and cycloalkyl-substituted imidazotriazinones BAYER AKTIENGESELLSCHAFT (DE) 2005-09-13 US disclosed
US-20050049250-A1 7-Aikyl and cycloalkyl-substituted imidazotriazinones BAYER AKTIENGESELLSCHAFT (DE) 2005-03-03 US disclosed
US-6838459-B1 7-alkyl-and cycloalkyl-substituted imidazotriazinones BAYER AKTIENGESELLSCHAFT (DE) 2005-01-04 US disclosed
US-6476029-B1 7-alkyl- and cycloalkyl-substituted imidazotriazinones BAYER AKTIENGESELLSCHAFT (DE) 2002-11-05 US disclosed
EP-1090003-A1 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES Bayer Aktiengesellschaft (DE) 2001-04-11 EP disclosed
WO-1999067244-A1 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049250-A1 7-Aikyl and cycloalkyl-substituted imidazotriazinones PDE3A, PDE2A, PDE3B HDAC1 2502/4885HDAC2 1832/4885CHRM1 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.